-+ 0.00%
-+ 0.00%
-+ 0.00%

ESTRELLA IMMUNOPHARMA COMPLETES SECOND DOSE COHORT IN STARLIGHT-1 TRIAL OF EB103 WITH COMPLETE RESPONSES IN ALL EVALUABLE PATIENTS

Reuters·11/03/2025 13:00:08

Please log in to view news